Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vera Therapeutics, Inc. (VERA)
USD42.31
-0.82 (-1.91%)
US NASDAQ Healthcare Biotechnology
Address
8000 Marina Boulevard 94005
Brisbane, CA, US
Brisbane, CA, US
CEO
Gary Barrera
Website
veratx.com
IPO
2021-05-14
CIK 1831828 ISIN US92337R1014
Description
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
News Sentiment (7d)
6 articles
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewsWire
- Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript Seeking Alpha
- US FDA approves Vera's kidney disease drug Reuters
- What's Going on with Vera Therapeutics Stock on Monday? Benzinga
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD42.31
-0.82 (-1.91%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.95
Float Shares
57.97M
Free Float %
80.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.16% | +0.38% | -18.72% | -13.33% | +17.79% | -27.71% | +62.78% | +383.62% | +218.35% | +218.35% | +218.35% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
42.31
Low
33.00
-22.0%
Consensus
77.60
+83.4%
Median
90.00
+112.7%
High
97.00
+129.3%
DCF (Unlevered)
4.05
-90.4%
DCF (Levered)
4.32
-89.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
93% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 12 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 6 |
75.50
+78.5%
|
| All Time | 13 |
49.77
+17.6%
|
Quality scores
Altman Z-Score
10.10
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-69.5% Q1'26: -108.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +2,271.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+16.1% Q1'26: +12.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.27× Q1'26: -0.15× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 6 EPS Ana. |
Dec 2027 8 Rev. Ana. 8 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
42.46M
9.94M – 103.82M
|
269.41M
149.02M – 582.74M
+534.4% YoY
|
696.54M
682.90M – 710.17M
+158.5% YoY
|
1.10B
544.66M – 2.20B
+58.1% YoY
|
1.46B
720.22M – 2.90B
+32.2% YoY
|
| EBITDA |
-144.42M
|
-291.62M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-144.52M
|
-292.08M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-152.15M
est: -158.30M (+3.9%)
|
-299.62M
est: -299.62M (+0.0%)
|
-377.24M
-436.01M – -314.03M
-25.9% YoY
|
-236.15M
-312.78M – -96.09M
+37.4% YoY
|
87.39M
-71.40M – 251.26M
+137.0% YoY
|
233.63M
80.14M – 535.34M
+167.3% YoY
|
399.26M
136.96M – 914.87M
+70.9% YoY
|
| SGA |
41.00M
|
100.22M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.75
est: -2.87 (+4.1%)
|
-4.66
est: -4.58 (-1.7%)
|
-5.60
-6.79 – -4.89
-22.1% YoY
|
-3.37
-4.87 – -1.50
+39.7% YoY
|
0.88
-1.11 – 3.91
+126.2% YoY
|
3.64
1.25 – 8.33
+311.2% YoY
|
6.22
2.13 – 14.24
+70.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-185.27M
OE per share TTM
-3.10
Owner's Yield
-8.04%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
749.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
36
Total invested
93.92M
Insider transactions (90d)
0
Beneficial owners (>5%)
31
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Avoro Capital Advisors LLC | 4.31M | 7.90% | 4.31M | — | 4.31M | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 2 | Behzad Aghazadeh | 4.31M | 7.90% | 4.31M | — | 4.31M | — | IN | Delaware | 2024-11-14 | ↗ |
| 3 | 52-0556948 | 3.94M | 7.20% | 3.87M | — | 3.94M | — | IA | Maryland | 2024-11-14 | ↗ |
| 4 | Juliet Tammenoms Bakker | 3.10M | 15.10% | — | 3.10M | — | 3.10M | IN | — | 2021-05-27 | ↗ |
| 5 | Longitude Capital Partners IV, LLC | 3.10M | 15.10% | — | 3.10M | — | 3.10M | OO | — | 2021-05-27 | ↗ |
| 6 | Longitude Venture Partners IV, L.P. | 3.10M | 15.10% | — | 3.10M | — | 3.10M | PN | — | 2021-05-27 | ↗ |
| 7 | Patrick G. Enright | 3.10M | 15.10% | — | 3.10M | — | 3.10M | IN | — | 2021-05-27 | ↗ |
| 8 | 98-0518585 | 2.96M | 14.60% | — | — | — | — | PN | England | 2021-05-24 | ↗ |
| 9 | LP | 2.96M | 14.60% | — | — | — | — | PN | England | 2021-05-24 | ↗ |
| 10 | Dr. James I. Healy (“Healy”) | 2.91M | 14.50% | — | 2.91M | — | 2.91M | IN | U.S. Citizen | 2021-05-24 | ↗ |
| 11 | Dr. Maha Katabi (“Katabi”) | 2.91M | 14.50% | — | 2.91M | — | 2.91M | IN | Canadian Citizen | 2021-05-24 | ↗ |
| 12 | Dr. Michael F. Powell (“Powell”) | 2.91M | 14.50% | — | 2.91M | — | 2.91M | IN | U.S. Citizen | 2021-05-24 | ↗ |
| 13 | Sofinnova Management X, L.L.C. (“SM X”) | 2.91M | 14.50% | 2.91M | — | 2.91M | 10.00 | OO | Delaware | 2021-05-24 | ↗ |
| 14 | Sofinnova Venture Partners X, L.P. (“SVP X”) | 2.91M | 14.50% | 2.91M | — | 2.91M | — | PN | Delaware | 2021-05-24 | ↗ |
| 15 | (1) BlackRock, Inc. | 2.75M | 6.20% | 2.70M | — | 2.75M | — | HC | Delaware | 2024-01-29 | ↗ |
| 16 | Capital LP | 2.34M | 5.60% | — | 2.34M | — | 2.34M | IA | Delaware USA | 2023-02-16 | ↗ |
| 17 | Capital Master LP | 2.34M | 5.60% | — | 2.34M | — | 2.34M | OO | Delaware USA | 2023-02-16 | ↗ |
| 18 | Peter Kolchinsky | 2.00M | 7.50% | — | 2.00M | — | — | HC, IN | Delaware | 2022-02-24 | ↗ |
| 19 | RA Capital Healthcare Fund, L.P. | 2.00M | 7.50% | — | 2.00M | — | — | PN | Delaware | 2022-02-24 | ↗ |
| 20 | RA Capital Management, L.P. | 2.00M | 7.50% | — | 2.00M | — | — | IA, PN | Delaware | 2022-02-24 | ↗ |
| 21 | Rajeev Shah | 2.00M | 7.50% | — | 2.00M | — | — | HC, IN | Delaware | 2022-02-24 | ↗ |
| 22 | Ares Trading SA | 1.91M | 8.99% | 1.91M | — | 1.91M | — | CO | Switzerland | 2022-01-24 | ↗ |
| 23 | KGaA, Darmstadt, Germany | 1.91M | 8.99% | 1.91M | — | 1.91M | — | CO | Switzerland | 2022-01-24 | ↗ |
| 24 | Merck KGaA, Darmstadt, Germany | 1.91M | 8.99% | 1.91M | — | 1.91M | — | CO | Switzerland | 2022-01-24 | ↗ |
| 25 | Kynam Capital Management GP, LLC | 1.41M | 5.10% | — | 1.41M | — | — | OO | U.S. | 2023-02-10 | ↗ |
| 26 | Kynam Capital Management, LP | 1.41M | 5.10% | — | 1.41M | — | — | IA | U.S. | 2023-02-10 | ↗ |
| 27 | Yue Tang | 1.41M | 5.10% | — | 1.41M | — | — | IN | U.S. | 2023-02-10 | ↗ |
| 28 | KPCB XVI Associates, LLC | 1.34M | 6.40% | 1.34M | 1.34M | 1.34M | 1.34M | OO | Delaware | 2022-02-11 | ↗ |
| 29 | Kleiner Perkins Caufield & Byers XVI, LLC (“KPCB XVI”) | 1.30M | 6.20% | 1.30M | 1.30M | 1.30M | 1.30M | OO | Delaware | 2022-02-11 | ↗ |
| 30 | Woodline Partners LP | 1.14M | 2.20% | 1.14M | — | 1.14M | — | IA | Delaware | 2024-02-12 | ↗ |
| 31 | KPCB XVI Founders Fund, LLC (“KPCB XVI Founders”) | 44.5K | 0.20% | 44.5K | 44.5K | 44.5K | 44.5K | OO | Delaware | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
36
-187 vs prev Q
New positions
7
Closed positions
187
Increased
20
Reduced
10
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 32.7K +32.7K (+100.0%) | 1.66B +1.7B (+100.0%) | 0.05% +0.051 pp | 1.60% +1.602 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 2 | AVORO CAPITAL ADVISORS LLC | 5.89M -321.1K (-5.2%) | 298.21M +117.8M (+65.2%) | 9.22% -0.512 pp | 2.87% +0.534 pp | USD40.29 +25.7% | 8 qtrs — |
| 3 | PRICE T ROWE ASSOCIATES INC /MD/ | 5.46M +1.8M (+49.0%) | 276.60M +170.0M (+159.6%) | 8.55% +2.807 pp | 0.03% +0.018 pp | USD43.13 +17.4% | 8 qtrs — |
| 4 | BLACKROCK, INC. | 4.83M +578.3K (+13.6%) | 244.36M +120.9M (+98.0%) | 7.56% +0.900 pp | 0.00% +0.002 pp | USD43.57 +16.2% | 6 qtrs — |
| 5 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4.06M +418.5K (+11.5%) | 205.58M +99.8M (+94.3%) | 6.36% +0.650 pp | 2.63% +1.010 pp | USD26.87 +88.5% | 4 qtrs — |
| 6 | VANGUARD GROUP INC | 3.57M +379.7K (+11.9%) | 180.81M +88.1M (+95.0%) | 5.59% +0.590 pp | 0.00% +0.001 pp | USD29.05 +74.3% | 19 qtrs — |
| 7 | KYNAM CAPITAL MANAGEMENT, LP | 3.43M -594.7K (-14.8%) | 173.85M +56.8M (+48.5%) | 5.38% -0.937 pp | 11.11% +2.391 pp | USD20.81 +143.3% | 17 qtrs — |
| 8 | EVERSEPT PARTNERS, LP | 3.07M +264.5K (+9.4%) | 155.58M +74.0M (+90.7%) | 4.81% +0.410 pp | 7.84% +2.217 pp | USD21.94 +130.8% | 14 qtrs — |
| 9 | FMR LLC | 2.89M +42.7K (+1.5%) | 146.14M +63.5M (+76.9%) | 4.52% +0.063 pp | 0.01% +0.003 pp | USD19.87 +154.9% | 19 qtrs — |
| 10 | DEEP TRACK CAPITAL, LP | 2.82M +2.8M (+100.0%) | 142.86M +142.9M (+100.0%) | 4.42% +4.419 pp | 2.55% +2.547 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 11 | SOFINNOVA INVESTMENTS, INC. | 2.79M +— (+0.0%) | 141.49M +60.3M (+74.3%) | 4.38% -0.004 pp | 6.10% +1.661 pp | USD13.59 +272.6% | 19 qtrs — |
| 12 | STATE STREET CORP | 2.68M +343.0K (+14.7%) | 135.54M +67.7M (+99.9%) | 4.19% +0.534 pp | 0.00% +0.002 pp | USD24.68 +105.2% | 18 qtrs — |
| 13 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.80M +100.0K (+5.9%) | 91.15M +41.8M (+84.5%) | 2.82% +0.154 pp | 4.53% +1.184 pp | USD38.26 +32.4% | 8 qtrs — |
| 14 | POINT72 ASSET MANAGEMENT, L.P. | 1.74M +466.4K (+36.7%) | 88.03M +51.1M (+138.1%) | 2.72% +0.729 pp | 0.10% +0.037 pp | USD34.85 +45.3% | 2 qtrs — |
| 15 | BELLEVUE GROUP AG | 1.70M +1.7M (+100.0%) | 85.99M +86.0M (+100.0%) | 2.66% +2.660 pp | 1.63% +1.630 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.44M +123.4K (+9.3%) | 73.19M +34.8M (+90.5%) | 2.26% +0.191 pp | 0.00% +0.002 pp | USD26.19 +93.4% | 19 qtrs — |
| 17 | PICTET ASSET MANAGEMENT HOLDING SA | 1.39M -46.7K (-3.2%) | 70.51M +28.7M (+68.6%) | 2.18% -0.075 pp | 0.07% +0.028 pp | USD25.78 +96.4% | 10 qtrs — |
| 18 | HOLOCENE ADVISORS, LP | 1.31M +1.3M (+100.0%) | 66.21M +66.2M (+100.0%) | 2.05% +2.048 pp | 0.14% +0.139 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 19 | ALLIANCEBERNSTEIN L.P. | 1.22M +1.2M (+2,217.2%) | 61.71M +60.2M (+3,938.0%) | 1.91% +1.826 pp | 0.02% +0.019 pp | USD49.39 +2.5% | 11 qtrs — |
| 20 | GOLDMAN SACHS GROUP INC | 1.12M +362.2K (+47.7%) | 56.76M +34.7M (+157.5%) | 1.76% +0.566 pp | 0.01% +0.004 pp | USD32.56 +55.5% | 11 qtrs — |
| 21 | WOODLINE PARTNERS LP | 1.00M +262.7K (+35.6%) | 50.65M +29.2M (+136.3%) | 1.57% +0.410 pp | 0.20% +0.095 pp | USD28.89 +75.3% | 14 qtrs — |
| 22 | FIRST LIGHT ASSET MANAGEMENT, LLC | 869.7K +362.6K (+71.5%) | 44.04M +29.3M (+198.9%) | 1.36% +0.567 pp | 3.37% +1.978 pp | USD44.67 +13.4% | 8 qtrs — |
| 23 | TRI LOCUM PARTNERS LP | 805.7K -384.5K (-32.3%) | 40.80M +6.2M (+18.0%) | 1.26% -0.604 pp | 5.30% -2.652 pp | USD27.21 +86.1% | 4 qtrs — |
| 24 | BRAIDWELL LP | 784.7K +312.0K (+66.0%) | 39.74M +26.0M (+189.3%) | 1.23% +0.488 pp | 1.27% +0.863 pp | USD37.64 +34.5% | 2 qtrs — |
| 25 | CITADEL ADVISORS LLC | 777.5K -837.9K (-51.9%) | 39.37M -7.6M (-16.1%) | 1.22% -1.315 pp | 0.01% -0.001 pp | USD27.77 +82.4% | 19 qtrs — |
| 26 | AMERICAN CENTURY COMPANIES INC | 732.7K +24.3K (+3.4%) | 37.10M +16.5M (+80.2%) | 1.15% +0.037 pp | 0.02% +0.008 pp | USD31.26 +62.0% | 7 qtrs — |
| 27 | CAPTION MANAGEMENT, LLC | 702.2K +702.2K (+100.0%) | 35.56M +35.6M (+100.0%) | 1.10% +1.100 pp | 0.24% +0.244 pp | USD50.64 +0.0% | 4 qtrs — |
| 28 | BANK OF AMERICA CORP /DE/ | 694.3K +203.8K (+41.6%) | 35.16M +20.9M (+146.7%) | 1.09% +0.319 pp | 0.00% +0.002 pp | USD32.98 +53.5% | 19 qtrs — |
| 29 | ARMISTICE CAPITAL, LLC | 653.8K +117.8K (+22.0%) | 33.11M +17.5M (+112.6%) | 1.02% +0.184 pp | 0.39% +0.163 pp | USD34.16 +48.2% | 5 qtrs — |
| 30 | FIRST TURN MANAGEMENT, LLC | 601.8K +247.2K (+69.7%) | 30.47M +20.2M (+195.8%) | 0.94% +0.387 pp | 3.48% +1.935 pp | USD42.06 +20.4% | 8 qtrs — |
| 31 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 568.6K -48.8K (-7.9%) | 28.79M +10.9M (+60.5%) | 0.89% -0.077 pp | 1.48% +0.428 pp | USD38.04 +33.1% | 8 qtrs — |
| 32 | VESTAL POINT CAPITAL, LP | 550.0K -210.0K (-27.6%) | 27.85M +5.8M (+26.1%) | 0.86% -0.330 pp | 0.95% -0.050 pp | USD30.27 +67.3% | 5 qtrs — |
| 33 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 518.9K +53.0K (+11.4%) | 26.27M +12.7M (+94.1%) | 0.81% +0.082 pp | 0.00% +0.002 pp | USD27.14 +86.6% | 18 qtrs — |
| 34 | MORGAN STANLEY | 499.7K +225.1K (+82.0%) | 25.30M +17.3M (+217.2%) | 0.78% +0.352 pp | 0.00% +0.001 pp | USD36.07 +40.4% | 19 qtrs — |
| 35 | BNP PARIBAS ARBITRAGE, SNC | 474.7K +220.7K (+86.9%) | 24.04M +16.7M (+225.7%) | 0.74% +0.345 pp | 0.01% +0.007 pp | USD38.54 +31.4% | 5 qtrs — |
| 36 | NORTHERN TRUST CORP | 473.2K +12.0K (+2.6%) | 23.96M +10.6M (+78.8%) | 0.74% +0.018 pp | 0.00% +0.001 pp | USD24.59 +105.9% | 18 qtrs — |
| 37 | CANDRIAM S.C.A. | 449.6K +22.4K (+5.2%) | 22.77M +10.4M (+83.4%) | 0.70% +0.034 pp | 0.11% +0.048 pp | USD37.69 +34.4% | 8 qtrs — |
| 38 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 420.0K +290.0K (+223.1%) | 21.27M +17.5M (+463.0%) | 0.66% +0.454 pp | 1.99% +1.570 pp | USD43.96 +15.2% | 2 qtrs — |
| 39 | VOYA INVESTMENT MANAGEMENT LLC | 419.0K +2.6K (+0.6%) | 21.22M +9.1M (+75.3%) | 0.66% +0.004 pp | 0.02% +0.009 pp | USD41.82 +21.1% | 11 qtrs — |
| 40 | QUBE RESEARCH & TECHNOLOGIES LTD | 378.1K -83.4K (-18.1%) | 19.14M +5.7M (+42.8%) | 0.59% -0.131 pp | 0.02% +0.006 pp | USD31.81 +59.2% | 8 qtrs — |
| 41 | FRONTIER CAPITAL MANAGEMENT CO LLC | 371.2K +371.2K (+100.0%) | 18.80M +18.8M (+100.0%) | 0.58% +0.581 pp | 0.20% +0.199 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 42 | ORBIMED ADVISORS LLC | 353.5K +353.5K (+100.0%) | 17.90M +17.9M (+100.0%) | 0.55% +0.554 pp | 0.37% +0.367 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 43 | DIMENSIONAL FUND ADVISORS LP | 351.9K -8.4K (-2.3%) | 17.82M +7.3M (+70.2%) | 0.55% -0.014 pp | 0.00% +0.002 pp | USD26.40 +91.8% | 9 qtrs — |
| 44 | DEUTSCHE BANK AG\ | 347.4K -286.4K (-45.2%) | 17.59M -825.2K (-4.5%) | 0.54% -0.450 pp | 0.01% 0.000 pp | USD22.13 +128.8% | 18 qtrs — |
| 45 | TD ASSET MANAGEMENT INC | 325.6K +115.1K (+54.7%) | 16.49M +10.4M (+169.5%) | 0.51% +0.180 pp | 0.01% +0.008 pp | USD43.71 +15.9% | 8 qtrs — |
| 46 | BARCLAYS PLC | 253.7K +168.3K (+197.1%) | 12.85M +9.1M (+240.4%) | 0.40% +0.264 pp | 0.00% +0.002 pp | USD42.59 +18.9% | 16 qtrs — |
| 47 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 252.5K +252.5K (+100.0%) | 12.78M +12.8M (+100.0%) | 0.40% +0.395 pp | 0.19% +0.193 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 48 | AFFINITY ASSET ADVISORS, LLC | 250.0K -53.3K (-17.6%) | 12.66M +3.8M (+43.6%) | 0.39% -0.084 pp | 0.72% -0.047 pp | USD35.97 +40.8% | 8 qtrs — |
| 49 | ALPHABET INC. | 241.3K +— (+0.0%) | 12.22M +5.2M (+74.3%) | 0.38% 0.000 pp | 0.47% +0.183 pp | USD13.26 +281.9% | 19 qtrs — |
| 50 | NUVEEN, LLC | 227.1K -90.6K (-28.5%) | 11.50M +2.3M (+24.6%) | 0.36% -0.142 pp | 0.00% +0.001 pp | USD27.33 +85.3% | 4 qtrs — |
| 51 | TWO SIGMA INVESTMENTS, LP | 210.0K +38.3K (+22.3%) | 10.63M +5.6M (+113.1%) | 0.33% +0.060 pp | 0.02% +0.008 pp | USD29.59 +71.1% | 13 qtrs — |
| 52 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 208.0K +68.4K (+49.0%) | 10.63M +6.6M (+162.0%) | 0.33% +0.107 pp | 0.01% +0.005 pp | USD41.67 +21.5% | 11 qtrs — |
| 53 | UBS GROUP AG | 207.3K +45.2K (+27.9%) | 10.50M +5.8M (+122.9%) | 0.32% +0.071 pp | 0.00% +0.001 pp | USD31.17 +62.5% | 16 qtrs — |
| 54 | UBS ASSET MANAGEMENT AMERICAS INC | 203.0K +120.7K (+146.7%) | 10.28M +7.9M (+329.8%) | 0.32% +0.189 pp | 0.00% +0.002 pp | USD41.80 +21.1% | 9 qtrs — |
| 55 | MILLENNIUM MANAGEMENT LLC | 199.7K -398.7K (-66.6%) | 10.11M -7.3M (-41.8%) | 0.31% -0.625 pp | 0.00% -0.003 pp | USD29.74 +70.3% | 8 qtrs — |
| 56 | RENAISSANCE TECHNOLOGIES LLC | 193.4K +193.4K (+100.0%) | 9.79M +9.8M (+100.0%) | 0.30% +0.303 pp | 0.02% +0.015 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 57 | CITIGROUP INC | 174.3K +165.1K (+1,807.8%) | 8.82M +8.6M (+3,224.5%) | 0.27% +0.259 pp | 0.00% +0.004 pp | USD49.94 +1.4% | 18 qtrs — |
| 58 | BANK OF NEW YORK MELLON CORP | 169.7K +8.2K (+5.1%) | 8.60M +3.9M (+83.1%) | 0.27% +0.013 pp | 0.00% +0.001 pp | USD23.93 +111.6% | 18 qtrs — |
| 59 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 154.6K +154.1K (+37,052.2%) | 7.83M +7.8M (+65,116.7%) | 0.24% +0.241 pp | 0.01% +0.009 pp | USD50.57 +0.1% | 3 qtrs — |
| 60 | WELLS FARGO & COMPANY/MN | 145.2K +64.0K (+78.8%) | 7.35M +5.0M (+211.6%) | 0.23% +0.100 pp | 0.00% +0.001 pp | USD39.93 +26.8% | 18 qtrs — |
| 61 | NICHOLAS INVESTMENT PARTNERS, LP | 144.8K +144.8K (+100.0%) | 7.33M +7.3M (+100.0%) | 0.23% +0.227 pp | 0.53% +0.534 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 62 | CENTIVA CAPITAL, LP | 132.5K +132.5K (+100.0%) | 6.71M +6.7M (+100.0%) | 0.21% +0.208 pp | 0.05% +0.055 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 63 | RUSSELL INVESTMENTS GROUP, LTD. | 124.9K -38.3K (-23.5%) | 6.32M +1.6M (+33.4%) | 0.20% -0.060 pp | 0.01% +0.002 pp | USD27.36 +85.1% | 11 qtrs — |
| 64 | EXOME ASSET MANAGEMENT LLC | 124.4K -31.7K (-20.3%) | 6.30M +1.8M (+38.9%) | 0.19% -0.050 pp | 3.01% +0.266 pp | USD26.36 +92.1% | 3 qtrs — |
| 65 | SWEDBANK AB | 121.2K +71.2K (+142.4%) | 6.14M +4.7M (+322.4%) | 0.19% +0.111 pp | 0.01% +0.005 pp | USD41.74 +21.3% | 2 qtrs — |
| 66 | CANADA PENSION PLAN INVESTMENT BOARD | 120.6K +18.4K (+18.0%) | 6.11M +3.1M (+105.6%) | 0.19% +0.029 pp | 0.00% +0.002 pp | USD32.35 +56.5% | 2 qtrs — |
| 67 | PLATINUM INVESTMENT MANAGEMENT LTD | 119.4K -40.4K (-25.3%) | 6.05M +1.4M (+30.2%) | 0.19% -0.064 pp | 1.40% +1.097 pp | USD18.14 +179.2% | 11 qtrs — |
| 68 | GW&K INVESTMENT MANAGEMENT, LLC | 113.8K +36.7K (+47.6%) | 5.76M +3.5M (+157.1%) | 0.18% +0.057 pp | 0.05% +0.030 pp | USD41.76 +21.3% | 5 qtrs — |
| 69 | PFM HEALTH SCIENCES, LP | 107.7K -406.0K (-79.0%) | 5.45M -9.5M (-63.5%) | 0.17% -0.637 pp | 0.54% -0.604 pp | USD29.06 +74.3% | 2 qtrs — |
| 70 | PARKMAN HEALTHCARE PARTNERS LLC | 100.6K +3.8K (+4.0%) | 5.09M +2.3M (+81.2%) | 0.16% +0.006 pp | 0.48% +0.192 pp | USD24.88 +103.5% | 4 qtrs — |
| 71 | INVESCO LTD. | 89.9K +59.2K (+193.3%) | 4.55M +3.7M (+411.1%) | 0.14% +0.093 pp | 0.00% +0.001 pp | USD41.28 +22.7% | 11 qtrs — |
| 72 | RAFFERTY ASSET MANAGEMENT, LLC | 85.8K -1.7K (-1.9%) | 4.35M +1.8M (+71.0%) | 0.13% -0.003 pp | 0.02% +0.007 pp | USD19.50 +159.7% | 10 qtrs — |
| 73 | SOVIERO ASSET MANAGEMENT, LP | 85.0K -15.0K (-15.0%) | 4.30M +1.4M (+48.1%) | 0.13% -0.024 pp | 2.06% +0.554 pp | USD27.41 +84.8% | 3 qtrs — |
| 74 | SWISS NATIONAL BANK | 75.6K -4.8K (-6.0%) | 3.83M +1.5M (+63.9%) | 0.12% -0.008 pp | 0.00% +0.001 pp | USD25.47 +98.8% | 10 qtrs — |
| 75 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 72.7K +72.7K (+100.0%) | 3.68M +3.7M (+100.0%) | 0.11% +0.114 pp | 0.03% +0.029 pp | USD50.64 +0.0% | 9 qtrs — |
| 76 | JANE STREET GROUP, LLC | 67.6K +2.3K (+3.5%) | 3.42M +1.5M (+80.4%) | 0.11% +0.004 pp | 0.00% +0.000 pp | USD24.48 +106.9% | 6 qtrs — |
| 77 | RHUMBLINE ADVISERS | 66.5K -6.4K (-8.8%) | 3.37M +1.2M (+58.9%) | 0.10% -0.010 pp | 0.00% +0.001 pp | USD22.87 +121.4% | 16 qtrs — |
| 78 | RAYMOND JAMES FINANCIAL INC | 64.9K +6.4K (+10.9%) | 3.29M +1.6M (+93.2%) | 0.10% +0.010 pp | 0.00% +0.001 pp | USD36.53 +38.6% | 5 qtrs — |
| 79 | ALGERT GLOBAL LLC | 64.9K -228.5K (-77.9%) | 3.29M -5.2M (-61.5%) | 0.10% -0.358 pp | 0.05% -0.092 pp | USD26.75 +89.3% | 8 qtrs — |
| 80 | CINCTIVE CAPITAL MANAGEMENT LP | 64.6K -32.0K (-33.1%) | 3.27M +465.8K (+16.6%) | 0.10% -0.050 pp | 0.18% +0.043 pp | USD26.35 +92.2% | 7 qtrs — |
| 81 | JPMORGAN CHASE & CO | 64.1K -18.3K (-22.2%) | 3.25M +852.9K (+35.6%) | 0.10% -0.029 pp | 0.00% +0.000 pp | USD26.24 +93.0% | 18 qtrs — |
| 82 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 61.6K -4.9K (-7.4%) | 3.12M +1.2M (+61.4%) | 0.10% -0.008 pp | 0.00% +0.000 pp | USD25.06 +102.1% | 12 qtrs — |
| 83 | EASTERN BANK | 56.1K +— (+0.0%) | 2.84M +1.2M (+74.3%) | 0.09% 0.000 pp | 0.05% +0.020 pp | USD44.20 +14.6% | 6 qtrs — |
| 84 | BALYASNY ASSET MANAGEMENT L.P. | 54.3K +54.3K (+100.0%) | 2.75M +2.8M (+100.0%) | 0.09% +0.085 pp | 0.00% +0.004 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 85 | ALPS ADVISORS INC | 52.4K +21.6K (+70.4%) | 2.65M +1.8M (+196.9%) | 0.08% +0.034 pp | 0.02% +0.011 pp | USD35.38 +43.1% | 15 qtrs — |
| 86 | J. SAFRA SARASIN HOLDING AG | 52.3K -3.0K (-5.4%) | 2.65M +1.0M (+64.8%) | 0.08% -0.005 pp | 0.04% +0.017 pp | USD26.12 +93.9% | 3 qtrs — |
| 87 | TUDOR INVESTMENT CORP ET AL | 50.1K +50.1K (+100.0%) | 2.54M +2.5M (+100.0%) | 0.08% +0.079 pp | 0.00% +0.005 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 88 | TREXQUANT INVESTMENT LP | 50.1K -158.4K (-76.0%) | 2.53M -3.5M (-58.2%) | 0.08% -0.249 pp | 0.02% -0.040 pp | USD27.28 +85.6% | 8 qtrs — |
| 89 | LEGAL & GENERAL GROUP PLC | 46.4K -4.8K (-9.4%) | 2.35M +861.3K (+57.8%) | 0.07% -0.008 pp | 0.00% +0.000 pp | USD27.21 +86.1% | 18 qtrs — |
| 90 | BIRCHVIEW CAPITAL, LP | 44.0K +44.0K (+100.0%) | 2.23M +2.2M (+100.0%) | 0.07% +0.069 pp | 1.30% +1.305 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 91 | HEADLANDS TECHNOLOGIES LLC | 42.8K +34.8K (+435.8%) | 2.17M +1.9M (+833.7%) | 0.07% +0.055 pp | 0.18% +0.162 pp | USD46.61 +8.6% | 2 qtrs — |
| 92 | HENNION & WALSH ASSET MANAGEMENT, INC. | 42.4K +10.1K (+31.2%) | 2.15M +1.2M (+128.7%) | 0.07% +0.016 pp | 0.07% +0.040 pp | USD31.73 +59.6% | 3 qtrs — |
| 93 | E. OHMAN J:OR ASSET MANAGEMENT AB | 39.5K +39.5K (+100.0%) | 2.00M +2.0M (+100.0%) | 0.06% +0.062 pp | 0.05% +0.047 pp | USD50.64 +0.0% | 1 qtrs NEW |
| 94 | NEW YORK STATE COMMON RETIREMENT FUND | 38.0K +20.1K (+112.1%) | 1.93M +1.4M (+269.5%) | 0.06% +0.031 pp | 0.00% +0.002 pp | USD41.05 +23.4% | 18 qtrs — |
| 95 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 37.8K -2.8K (-6.9%) | 1.92M +735.5K (+62.3%) | 0.06% -0.004 pp | 0.00% +0.001 pp | USD23.89 +112.0% | 18 qtrs — |
| 96 | SECTORAL ASSET MANAGEMENT INC | 36.9K +6.7K (+22.1%) | 1.87M +989.2K (+112.8%) | 0.06% +0.010 pp | 1.50% +0.955 pp | USD26.90 +88.3% | 12 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 103 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 1.54% | 3.28M | 0.50% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 1.03% | 370.5K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 1.03% | 111.61M | 0.35% |
| 4 | Virtus Biotech Clinical Trials ETF BBC | 0.75% | 434.3K | 0.65% |
| 5 | Optimize Strategy Index ETF OPTZ | 0.40% | 957.5K | 0.25% |
| 6 | Xtrackers S&P 500 Swap UCITS ETF 5C EUR Hedged XS5E.DE | 0.38% | 39.46M | 0.20% |
| 7 | Xtrackers S&P 500 Swap UCITS ETF 1D XSXD.L | 0.38% | 39.52M | 0.07% |
| 8 | Xtrackers S&P 500 Swap UCITS ETF XS5G.L | 0.38% | 39.48M | 0.20% |
| 9 | Xtrackers S&P 500 Swap UCITS ETF 1C XSPU.L | 0.38% | 39.52M | 0.15% |
| 10 | American Century Small Cap Growth Insights ETF ACSG | 0.34% | 86.6K | 0.49% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
23.0K
Cash buys
—
Cash sales
3.00
Net activity
-22,951
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | Fordyce Marshall | Director / Officer | S-Sale | D | Class A Common Stock | 14,130 | 43.66 | 617.0K | 244,065 | D | ↗ |
| 2026-03-23 | Wright-Mitchell Jane | Officer | A-Award | A | Stock Option (right to buy) | 56,850 | 40.73 | 2.32M | 56,850 | D | ↗ |
| 2026-03-13 | Young Joseph R | Officer | M-Exempt | A | Class A Common Stock | 10,000 | 3.94 | 39.4K | 75,754 | D | ↗ |
| 2026-03-05 | Hite Christopher | Director | A-Award | A | Stock Option (right to buy) | 24,937 | 38.85 | 968.8K | 24,937 | D | ↗ |
| 2026-02-23 | Young Joseph R | Officer | S-Sale | D | Class A Common Stock | 3,117 | 41.98 | 130.9K | 64,722 | D | ↗ |
| 2026-02-23 | Turner William D. | Officer | S-Sale | D | Class A Common Stock | 2,187 | 41.98 | 91.8K | 45,313 | D | ↗ |
| 2026-02-23 | Skelton Laurence Matthew | Officer | S-Sale | D | Class A Common Stock | 1,582 | 41.98 | 66.4K | 64,218 | D | ↗ |
| 2026-02-23 | JOHNSON DAVID LEE | Officer | S-Sale | D | Class A Common Stock | 2,579 | 41.98 | 108.3K | 45,727 | D | ↗ |
| 2026-02-23 | Grant Sean | Officer | S-Sale | D | Class A Common Stock | 4,949 | 41.98 | 207.8K | 114,181 | D | ↗ |
| 2026-02-23 | Fordyce Marshall | Director / Officer | S-Sale | D | Class A Common Stock | 16,925 | 41.98 | 710.6K | 257,163 | D | ↗ |
| 2026-02-23 | Brenner Robert | Officer | S-Sale | D | Class A Common Stock | 2,151 | 41.98 | 90.3K | 50,947 | D | ↗ |
| 2026-02-04 | Young Joseph R | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 42.74 | 854.8K | 20,000 | D | ↗ |
| 2026-02-04 | Turner William D. | Officer | A-Award | A | Class A Common Stock | 25,000 | 0.00 | — | 47,500 | D | ↗ |
| 2026-02-04 | Skelton Laurence Matthew | Officer | A-Award | A | Class A Common Stock | 20,000 | 0.00 | — | 65,800 | D | ↗ |
| 2026-02-04 | JOHNSON DAVID LEE | Officer | A-Award | A | Class A Common Stock | 20,000 | 0.00 | — | 48,306 | D | ↗ |
| 2026-02-04 | Grant Sean | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 42.74 | 2.14M | 50,000 | D | ↗ |
| 2026-02-04 | Fordyce Marshall | Director / Officer | A-Award | A | Stock Option (right to buy) | 137,500 | 42.74 | 5.88M | 137,500 | D | ↗ |
| 2026-02-04 | Brenner Robert | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 42.74 | 2.14M | 50,000 | D | ↗ |
| 2026-01-20 | Skelton Laurence Matthew | Officer | — | — | Class A Common Stock | 0 | 0.00 | — | 30,000 | D | ↗ |
| 2025-12-15 | Turner William D. | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 15.53 | 155.3K | 245,000 | D | ↗ |
| 2025-12-11 | ENRIGHT PATRICK G | Director | P-Purchase | A | Class A Common Stock | 5,882 | 42.50 | 250.0K | 5,882 | D | ↗ |
| 2025-12-08 | Turner William D. | Officer | M-Exempt | A | Class A Common Stock | 10,000 | 15.53 | 155.3K | 32,500 | D | ↗ |
| 2025-12-03 | Turner William D. | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 15.53 | 155.3K | 265,000 | D | ↗ |
| 2025-11-25 | Meyers James R | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 29.43 | 735.8K | 25,000 | D | ↗ |
| 2025-11-21 | Carter Jason S | Officer | S-Sale | D | Class A Common Stock | 3,864 | 27.82 | 107.5K | 49,136 | D | ↗ |
| 2025-11-13 | Young Joseph R | Officer | M-Exempt | A | Class A Common Stock | 10,000 | 3.94 | 39.4K | 57,839 | D | ↗ |
| 2025-11-11 | Young Joseph R | Officer | S-Sale | D | Class A Common Stock | 15,000 | 29.06 | 435.9K | 47,839 | D | ↗ |
| 2025-06-24 | ENRIGHT PATRICK G | Director | P-Purchase | A | Class A Common Stock | 27,071 | 22.35 | 605.1K | 3,596,593 | I | ↗ |
| 2025-06-23 | ENRIGHT PATRICK G | Director | P-Purchase | A | Class A Common Stock | 139,595 | 20.87 | 2.91M | 3,569,522 | I | ↗ |
| 2025-05-14 | SEIDENBERG BETH C | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 21.19 | 296.7K | 14,000 | D | ↗ |
| 2025-05-14 | Oliger Christy J. | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 21.19 | 296.7K | 14,000 | D | ↗ |
| 2025-05-14 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 21.19 | 296.7K | 14,000 | D | ↗ |
| 2025-05-14 | MORRISSEY MICHAEL | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 21.19 | 296.7K | 14,000 | D | ↗ |
| 2025-05-14 | Katabi Maha | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 21.19 | 296.7K | 14,000 | D | ↗ |
| 2025-05-14 | Hall Kimball | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 21.19 | 296.7K | 14,000 | D | ↗ |
| 2025-05-14 | ENRIGHT PATRICK G | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 21.19 | 296.7K | 14,000 | D | ↗ |
| 2025-05-14 | Cheng Andrew | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 21.19 | 296.7K | 14,000 | D | ↗ |
| 2025-02-26 | Fordyce Marshall | Director / Officer | S-Sale | D | Class A Common Stock | 7,975 | 27.55 | 219.7K | 205,765 | D | ↗ |
| 2025-02-21 | Fordyce Marshall | Director / Officer | S-Sale | D | Class A Common Stock | 10,613 | 27.89 | 296.0K | 213,740 | D | ↗ |
| 2025-02-18 | Young Joseph R | Officer | A-Award | A | Stock Option (right to buy) | 21,500 | 29.18 | 627.4K | 21,500 | D | ↗ |
| 2025-02-18 | Turner William D. | Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 29.18 | 1.31M | 45,000 | D | ↗ |
| 2025-02-18 | JOHNSON DAVID LEE | Officer | A-Award | A | Class A Common Stock | 26,900 | 0.00 | — | 26,900 | D | ↗ |
| 2025-02-18 | Grant Sean | Officer | A-Award | A | Stock Option (right to buy) | 53,800 | 29.18 | 1.57M | 53,800 | D | ↗ |
| 2025-02-18 | Fordyce Marshall | Director / Officer | A-Award | A | Stock Option (right to buy) | 161,500 | 29.18 | 4.71M | 161,500 | D | ↗ |
| 2025-02-18 | Brenner Robert | Officer | A-Award | A | Class A Common Stock | 26,900 | 0.00 | — | 27,474 | D | ↗ |
| 2025-01-08 | Fordyce Marshall | Director / Officer | M-Exempt | A | Class A Common Stock | 5,650 | 2.90 | 16.4K | 149,253 | D | ↗ |
| 2024-12-19 | Fordyce Marshall | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 57,661 | 2.90 | 167.0K | 626,551 | D | ↗ |
| 2024-12-18 | Fordyce Marshall | Director / Officer | M-Exempt | A | Class A Common Stock | 1,875 | 2.90 | 5.4K | 87,817 | D | ↗ |
| 2024-12-11 | Fordyce Marshall | Director / Officer | M-Exempt | A | Class A Common Stock | 700 | 2.90 | 2.0K | 86,642 | D | ↗ |
| 2024-11-25 | Fordyce Marshall | Director / Officer | M-Exempt | A | Class A Common Stock | 1,381 | 2.90 | 4.0K | 87,323 | D | ↗ |
| 2024-11-18 | Carter Jason S | Officer | A-Award | A | Class A Common Stock | 53,000 | 0.00 | — | 53,000 | D | ↗ |
| 2024-11-13 | Fordyce Marshall | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,625 | 2.90 | 45.3K | 753,587 | D | ↗ |
| 2024-10-28 | SEIDENBERG BETH C | Director | S-Sale | D | Class A Common Stock | 14,798 | 48.01 | 710.5K | 131,755 | D | ↗ |
| 2024-10-23 | Fordyce Marshall | Director / Officer | M-Exempt | A | Class A Common Stock | 2,310 | 2.90 | 6.7K | 310,282 | D | ↗ |
| 2024-10-09 | Fordyce Marshall | Director / Officer | M-Exempt | A | Class A Common Stock | 3,352 | 2.90 | 9.7K | 311,324 | D | ↗ |
| 2024-09-25 | Fordyce Marshall | Director / Officer | M-Exempt | A | Class A Common Stock | 900 | 2.90 | 2.6K | 308,872 | D | ↗ |
| 2024-09-19 | SEIDENBERG BETH C | Director | S-Sale | D | Class A Common Stock | 13,823 | 42.31 | 584.8K | 146,553 | D | ↗ |
| 2024-09-18 | SEIDENBERG BETH C | Director | S-Sale | D | Class A Common Stock | 1,476 | 42.00 | 62.0K | 4,012 | I | ↗ |
| 2024-09-11 | Fordyce Marshall | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,625 | 2.90 | 45.3K | 827,337 | — | ↗ |
| 2024-08-28 | Fordyce Marshall | Director / Officer | S-Sale | D | Class A Common Stock | 14,925 | 36.80 | 549.2K | 322,667 | — | ↗ |
| 2024-08-21 | Fordyce Marshall | Director / Officer | S-Sale | D | Class A Common Stock | 14,471 | 39.76 | 575.4K | 322,667 | — | ↗ |
| 2024-08-14 | Fordyce Marshall | Director / Officer | S-Sale | D | Class A Common Stock | 15,625 | 37.56 | 586.9K | 337,138 | — | ↗ |
| 2024-07-01 | JOHNSON DAVID LEE | Officer | A-Award | A | Stock Option (right to buy) | 160,000 | 36.29 | 5.81M | 160,000 | — | ↗ |
| 2024-06-07 | Oliger Christy J. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 38.50 | 962.5K | 25,000 | — | ↗ |
| 2024-05-16 | Young Joseph R | Officer | M-Exempt | A | Class A Common Stock | 18,151 | 7.87 | 142.8K | 69,357 | — | ↗ |
| 2024-05-15 | Young Joseph R | Officer | M-Exempt | A | Class A Common Stock | 8,221 | 3.94 | 32.4K | 61,392 | — | ↗ |
| 2024-05-15 | SEIDENBERG BETH C | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 42.69 | 597.7K | 14,000 | — | ↗ |
| 2024-05-15 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 42.69 | 597.7K | 14,000 | — | ↗ |
| 2024-05-15 | MORRISSEY MICHAEL | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 42.69 | 597.7K | 14,000 | — | ↗ |
| 2024-05-15 | Katabi Maha | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 42.69 | 597.7K | 14,000 | — | ↗ |
| 2024-05-15 | Hall Kimball | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 42.69 | 597.7K | 14,000 | — | ↗ |
| 2024-05-15 | ENRIGHT PATRICK G | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 42.69 | 597.7K | 14,000 | — | ↗ |
| 2024-05-15 | Cheng Andrew | Director | A-Award | A | Stock Option (right to buy) | 14,000 | 42.69 | 597.7K | 14,000 | — | ↗ |
| 2024-04-10 | Young Joseph R | Officer | S-Sale | D | Class A Common Stock | 5,714 | 40.00 | 228.6K | 53,171 | — | ↗ |
| 2024-04-03 | Grant Sean | Officer | S-Sale | D | Class A Common Stock | 78 | 38.20 | 3.0K | 257 | — | ↗ |
| 2024-03-25 | Katabi Maha | Director | S-Sale | D | Class A Common Stock | 340,000 | 40.50 | 13.77M | 2,793,987 | — | ↗ |
| 2024-03-22 | Katabi Maha | Director | S-Sale | D | Class A Common Stock | 413,450 | 40.51 | 16.75M | 3,133,987 | — | ↗ |
| 2024-03-21 | Katabi Maha | Director | S-Sale | D | Class A Common Stock | 21,918 | 44.00 | 964.4K | 3,573,772 | — | ↗ |
| 2024-01-30 | Katabi Maha | Director | P-Purchase | A | Class A Common Stock | 161,290 | 31.00 | 5.00M | 3,628,446 | — | ↗ |
| 2024-01-16 | Young Joseph R | Officer | A-Award | A | Class A Common Stock | 21,875 | 0.00 | — | 57,054 | — | ↗ |
| 2024-01-16 | Grant Sean | Officer | A-Award | A | Stock Option (right to buy) | 97,500 | 16.80 | 1.64M | 97,500 | — | ↗ |
| 2024-01-16 | Fordyce Marshall | Director / Officer | A-Award | A | Class A Common Stock | 78,750 | 0.00 | — | 335,627 | — | ↗ |
| 2024-01-10 | COMMODORE CAPITAL LP | 10% Owner | S-Sale | D | Class A Common Stock | 1,050,000 | 18.00 | 18.90M | 4,400,000 | — | ↗ |
| 2024-01-05 | Turner William D. | Officer | A-Award | A | Stock Option (right to buy) | 275,000 | 15.53 | 4.27M | 275,000 | — | ↗ |
| 2024-01-03 | Brenner Robert | Officer | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-29 | Fordyce Marshall | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 516 | 2.32 | 1.2K | 0 | — | ↗ |
| 2023-12-20 | Grant Sean | Officer | G-Gift | D | Class A Common Stock | 636 | 0.00 | — | 18,021 | — | ↗ |
| 2023-08-21 | Lin Celia | Officer | S-Sale | D | Class A Common Stock | 1,490 | 16.65 | 24.8K | 11,010 | — | ↗ |
| 2023-08-21 | Fordyce Marshall | Director / Officer | S-Sale | D | Class A Common Stock | 5,210 | 16.66 | 86.8K | 243,361 | — | ↗ |
| 2023-08-21 | Curley Joanne | Officer | S-Sale | D | Class A Common Stock | 1,490 | 16.66 | 24.8K | 26,962 | — | ↗ |
| 2023-07-24 | Grant Sean | Officer | G-Gift | D | Class A Common Stock | 1,620 | 0.00 | — | 18,657 | — | ↗ |
| 2023-07-05 | Young Joseph R | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 3.94 | 39.4K | 66,810 | — | ↗ |
| 2023-06-23 | Grant Sean | Officer | P-Purchase | A | Class A Common Stock | 5,000 | 16.60 | 83.0K | 5,992 | — | ↗ |
| 2023-06-20 | COMMODORE CAPITAL LP | 10% Owner | P-Purchase | A | Class A Common Stock | 448,217 | 15.17 | 6.80M | 5,450,000 | — | ↗ |
| 2023-06-14 | COMMODORE CAPITAL LP | 10% Owner | — | I | Class A Common Stock | 0 | 0.00 | — | 5,001,783 | — | ↗ |
| 2023-05-10 | SEIDENBERG BETH C | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 7.70 | 154.0K | 20,000 | — | ↗ |
| 2023-05-10 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 7.70 | 154.0K | 20,000 | — | ↗ |
| 2023-05-10 | MORRISSEY MICHAEL | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 7.70 | 154.0K | 20,000 | — | ↗ |
| 2023-05-10 | Katabi Maha | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 7.70 | 154.0K | 20,000 | — | ↗ |
| 2023-05-10 | Hall Kimball | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 7.70 | 154.0K | 20,000 | — | ↗ |
| 2023-05-10 | ENRIGHT PATRICK G | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 20,000 | 7.70 | 154.0K | 20,000 | — | ↗ |
| 2023-05-10 | Cheng Andrew | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 7.70 | 154.0K | 20,000 | — | ↗ |
| 2023-03-30 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 2,300 | 7.24 | 16.7K | 1,949,295 | — | ↗ |
| 2023-03-28 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 23,908 | 7.24 | 173.2K | 1,946,995 | — | ↗ |
| 2023-03-27 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 1,633 | 7.24 | 11.8K | 1,923,087 | — | ↗ |
| 2023-03-24 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 1,833 | 7.24 | 13.3K | 1,921,454 | — | ↗ |
| 2023-03-20 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 15,252 | 7.21 | 110.0K | 1,919,621 | — | ↗ |
| 2023-03-17 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 74,045 | 7.12 | 526.9K | 1,904,369 | — | ↗ |
| 2023-03-16 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 60,097 | 7.09 | 426.3K | 1,830,324 | — | ↗ |
| 2023-03-15 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 32,844 | 7.12 | 234.0K | 1,770,227 | — | ↗ |
| 2023-03-14 | Grant Sean | Officer | G-Gift | D | Class A Common Stock | 14,285 | 0.00 | — | 35,648 | — | ↗ |
| 2023-03-10 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 48,003 | 7.16 | 343.5K | 1,737,383 | — | ↗ |
| 2023-03-03 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 1,000 | 7.25 | 7.2K | 1,689,380 | — | ↗ |
| 2023-03-02 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 23,378 | 7.24 | 169.3K | 1,688,380 | — | ↗ |
| 2023-03-01 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 100 | 7.25 | 725.00 | 1,665,002 | — | ↗ |
| 2023-02-23 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 200 | 7.24 | 1.4K | 1,664,902 | — | ↗ |
| 2023-02-15 | Young Joseph R | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 7.87 | 708.3K | 90,000 | — | ↗ |
| 2023-02-15 | Lin Celia | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 7.87 | 787.0K | 100,000 | — | ↗ |
| 2023-02-15 | Grant Sean | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 7.87 | 1.57M | 200,000 | — | ↗ |
| 2023-02-15 | Fordyce Marshall | Director / Officer | A-Award | A | Stock Option (right to buy) | 450,000 | 7.87 | 3.54M | 450,000 | — | ↗ |
| 2023-02-15 | Curley Joanne | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 7.87 | 1.18M | 150,000 | — | ↗ |
| 2023-02-13 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 10,072 | 7.20 | 72.5K | 1,664,702 | — | ↗ |
| 2023-02-09 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 400 | 7.25 | 2.9K | 1,654,630 | — | ↗ |
| 2023-02-08 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 45,357 | 7.22 | 327.5K | 1,654,230 | — | ↗ |
| 2023-02-07 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 87,956 | 7.08 | 622.7K | 1,608,873 | — | ↗ |
| 2023-02-06 | Young Joseph R | Officer | P-Purchase | A | Class A Common Stock | 5,714 | 7.00 | 40.0K | 22,679 | — | ↗ |
| 2023-02-06 | Sofinnova Venture Partners X, L.P. | 10% Owner | P-Purchase | A | Class A Common Stock | 285,714 | 7.00 | 2.00M | 3,467,156 | — | ↗ |
| 2023-02-06 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 131,602 | 7.03 | 925.2K | 1,520,917 | — | ↗ |
| 2023-02-06 | Longitude Prime Partners, LLC | 10% Owner | — | I | Class A Common Stock | 0 | 0.00 | — | 1,714,285 | — | ↗ |
| 2023-02-06 | Longitude Capital Partners IV, LLC | 10% Owner | P-Purchase | A | Class A Common Stock | 1,714,285 | 7.00 | 12.00M | 1,714,285 | — | ↗ |
| 2023-02-06 | Grant Sean | Officer | P-Purchase | A | Class A Common Stock | 14,285 | 7.00 | 100.0K | 49,933 | — | ↗ |
| 2023-02-06 | ENRIGHT PATRICK G | Director / 10% Owner | P-Purchase | A | Class A Common Stock | 1,714,285 | 7.00 | 12.00M | 1,714,285 | — | ↗ |
| 2023-02-03 | SEIDENBERG BETH C | Director | P-Purchase | A | Class A Common Stock | 46,163 | 7.24 | 334.2K | 1,389,315 | — | ↗ |
| 2022-12-16 | Curley Joanne | Officer | M-Exempt | D | Stock Option (right to buy) | 2,212 | 0.00 | — | 35,801 | — | ↗ |
| 2022-12-13 | Curley Joanne | Officer | M-Exempt | D | Stock Option (right to buy) | 11,733 | 0.00 | — | 65,384 | — | ↗ |
| 2022-12-12 | Curley Joanne | Officer | M-Exempt | D | Stock Options (right to buy) | 6,900 | 0.00 | — | 77,117 | — | ↗ |
| 2022-12-07 | Curley Joanne | Officer | S-Sale | D | Class A Common Stock | 494 | 16.47 | 8.1K | 26,821 | — | ↗ |
| 2022-11-17 | Curley Joanne | Officer | M-Exempt | D | Stock Option (right to buy) | 2,211 | 0.00 | — | 38,013 | — | ↗ |
| 2022-11-16 | Fordyce Marshall | Officer | M-Exempt | A | Class A Common Stock | 60,000 | 2.90 | 173.8K | 246,303 | — | ↗ |
| 2022-11-09 | Curley Joanne | Officer | S-Sale | D | Class A Common Stock | 494 | 16.54 | 8.2K | 27,315 | — | ↗ |
| 2022-10-18 | Curley Joanne | Officer | M-Exempt | D | Stock Options (right to buy) | 5,300 | 0.00 | — | 84,017 | — | ↗ |
| 2022-10-05 | Curley Joanne | Officer | S-Sale | D | Class A Common Stock | 988 | 21.64 | 21.4K | 27,809 | — | ↗ |
| 2022-10-04 | Fordyce Marshall | Officer | M-Exempt | A | Class A Common Stock | 6,899 | 2.90 | 20.0K | 188,049 | — | ↗ |
| 2022-10-03 | Fordyce Marshall | Officer | M-Exempt | A | Class A Common Stock | 2,408 | 2.90 | 7.0K | 183,558 | — | ↗ |
| 2022-09-07 | Fordyce Marshall | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,785 | 0.00 | — | 1,049,131 | — | ↗ |
| 2022-09-07 | Curley Joanne | Officer | S-Sale | D | Class A Common Stock | 988 | 18.63 | 18.4K | 28,797 | — | ↗ |
| 2022-09-01 | Fordyce Marshall | Officer | M-Exempt | D | Stock Option (Right to Buy) | 17,096 | 0.00 | — | 1,055,916 | — | ↗ |
| 2022-08-19 | Young Joseph R | Officer | A-Award | A | Class A Common Stock | 15,000 | 0.00 | — | 16,148 | — | ↗ |
| 2022-08-19 | Lin Celia | Officer | A-Award | A | Class A Common Stock | 12,500 | 0.00 | — | 12,500 | — | ↗ |
| 2022-08-19 | Grant Sean | Officer | A-Award | A | Class A Common Stock | 33,750 | 0.00 | — | 35,268 | — | ↗ |
| 2022-08-19 | Fordyce Marshall | Officer | A-Award | A | Class A Common Stock | 43,750 | 0.00 | — | 181,150 | — | ↗ |
| 2022-08-19 | Curley Joanne | Officer | M-Exempt | A | Class A Common Stock | 2,766 | 11.00 | 30.4K | 32,551 | — | ↗ |
| 2022-08-17 | Carlyle Group Inc. | 10% Owner | M-Exempt | D | Stock Option (right to buy) | 9,925 | 11.00 | 109.2K | 0 | — | ↗ |
| 2022-08-17 | Carlyle Genesis UK LLC | Director | S-Sale | D | Class A Common Stock | 172 | 21.07 | 3.6K | 2,960,231 | — | ↗ |
| 2022-08-12 | Fordyce Marshall | Officer | M-Exempt | D | Stock Option (right to buy) | 20,528 | 0.00 | — | 1,086,684 | — | ↗ |
| 2022-08-03 | Curley Joanne | Officer | S-Sale | D | Class A Common Stock | 988 | 16.81 | 16.6K | 17,285 | — | ↗ |
| 2022-08-01 | Carlyle Group Inc. | 10% Owner | — | I | Class A Common Stock | 0 | 0.00 | — | 2,960,231 | — | ↗ |
| 2022-07-19 | Curley Joanne | Officer | M-Exempt | A | Class A Common Stock | 8 | 2.90 | 23.17 | 18,281 | — | ↗ |
| 2022-07-14 | Curley Joanne | Officer | M-Exempt | D | Stock Option (right to buy) | 6,354 | 0.00 | — | 52,813 | — | ↗ |
| 2022-07-07 | Curley Joanne | Officer | M-Exempt | D | Stock Option (right to buy) | 3,487 | 0.00 | — | 19,419 | — | ↗ |
| 2022-06-22 | Curley Joanne | Officer | S-Sale | D | Class A Common Stock | 306 | 15.02 | 4.6K | 23,688 | — | ↗ |
| 2022-06-17 | Curley Joanne | Officer | S-Sale | D | Class A Common Stock | 1,346 | 15.08 | 20.3K | 25,194 | — | ↗ |
| 2022-06-15 | Grant Sean | Officer | P-Purchase | A | Class A Common Stock | 2,816 | 13.60 | 38.3K | 2,816 | — | ↗ |
| 2022-05-31 | Curley Joanne | Officer | M-Exempt | A | Class A Common Stock | 400 | 6.37 | 2.5K | 25,594 | — | ↗ |
| 2022-05-24 | SEIDENBERG BETH C | Director | A-Award | A | Stock Option (right to buy) | 9,925 | 0.00 | — | 9,925 | — | ↗ |
| 2022-05-24 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 9,925 | 0.00 | — | 9,925 | — | ↗ |
| 2022-05-24 | MORRISSEY MICHAEL | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-05-24 | Katabi Maha | Director | A-Award | A | Stock Option (right to buy) | 9,925 | 0.00 | — | 9,925 | — | ↗ |
| 2022-05-24 | Hall Kimball | Director | A-Award | A | Stock Option (right to buy) | 9,925 | 0.00 | — | 9,925 | — | ↗ |
| 2022-05-24 | ENRIGHT PATRICK G | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 9,925 | 16.14 | 160.2K | 9,925 | — | ↗ |
| 2022-05-24 | Cheng Andrew | Director | A-Award | A | Stock Option (right to buy) | 9,925 | 0.00 | — | 9,925 | — | ↗ |
| 2022-02-16 | Young Joseph R | Officer | A-Award | A | Stock Option (right to buy) | 36,729 | 20.94 | 769.1K | 36,729 | — | ↗ |
| 2022-02-16 | Lin Celia | Officer | A-Award | A | Stock Option (right to buy) | 52,412 | 20.94 | 1.10M | 52,412 | — | ↗ |
| 2022-02-16 | Grant Sean | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 20.94 | 1.88M | 90,000 | — | ↗ |
| 2022-02-16 | Fordyce Marshall | Director / Officer | A-Award | A | Stock Option (right to buy) | 176,154 | 20.94 | 3.69M | 176,154 | — | ↗ |
| 2022-02-16 | Curley Joanne | Officer | A-Award | A | Stock Option (right to buy) | 52,964 | 20.94 | 1.11M | 52,964 | — | ↗ |
| 2022-02-10 | Sofinnova Venture Partners X, L.P. | 10% Owner | P-Purchase | A | Class A Common Stock | 266,666 | 15.00 | 4.00M | 3,181,442 | — | ↗ |
| 2022-02-10 | Longitude Capital Partners IV, LLC | 10% Owner | P-Purchase | A | Class A Common Stock | 333,333 | 15.00 | 5.00M | 3,429,927 | — | ↗ |
| 2022-02-10 | ENRIGHT PATRICK G | Director / 10% Owner | P-Purchase | A | Class A Common Stock | 333,333 | 15.00 | 5.00M | 3,429,927 | — | ↗ |
| 2022-02-06 | Young Joseph R | Officer | P-Purchase | A | Class A Common Stock | 5,714 | 7.00 | 40.0K | 22,679 | — | ↗ |
| 2022-02-06 | Grant Sean | Officer | P-Purchase | A | Class A Common Stock | 14,285 | 7.00 | 100.0K | 49,933 | — | ↗ |
| 2021-12-10 | Hall Kimball | Director | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-13 | Grant Sean | Officer | A-Award | A | Stock Option (right to buy) | 180,000 | 14.87 | 2.68M | 180,000 | — | ↗ |
| 2021-07-12 | Grant Sean | Officer | — | D | No securities owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-18 | Sofinnova Venture Partners X, L.P. | 10% Owner | P-Purchase | A | Class A Common Stock | 727,272 | 11.00 | 8.00M | 2,914,776 | — | ↗ |
| 2021-05-18 | SEIDENBERG BETH C | Director | C-Conversion | D | Series B Preferred Stock | 100,526 | 0.00 | — | 0 | — | ↗ |
| 2021-05-18 | Longitude Capital Partners IV, LLC | 10% Owner | C-Conversion | D | Series C Preferred Stock | 2,187,504 | 0.00 | — | 0 | — | ↗ |
| 2021-05-18 | Katabi Maha | Director / 10% Owner | C-Conversion | D | Series C Preferred Stock | 2,187,504 | 0.00 | — | 0 | — | ↗ |
| 2021-05-18 | ENRIGHT PATRICK G | Director / 10% Owner | P-Purchase | A | Class A Common Stock | 909,090 | 11.00 | 10.00M | 3,096,594 | — | ↗ |
| 2021-05-18 | EMSTER KURT VON | Director | P-Purchase | A | Class A Common Stock | 772,727 | 11.00 | 8.50M | 2,960,231 | — | ↗ |
| 2021-05-18 | Cheng Andrew | Director | C-Conversion | A | Class A Common Stock | 17,488 | 0.00 | — | 17,488 | — | ↗ |
| 2021-05-18 | Abingworth LLP | 10% Owner | P-Purchase | A | Class A Common Stock | 772,727 | 11.00 | 8.50M | 2,960,231 | — | ↗ |
| 2021-05-17 | EMSTER KURT VON | Director | P-Purchase | A | Class A Common Stock | 17,828 | 12.04 | 214.7K | 17,828 | — | ↗ |
| 2021-05-13 | Young Joseph R | Officer | — | D | Stock Option (right to buy) | 76,810 | 3.94 | 302.6K | 0 | — | ↗ |
| 2021-05-13 | Wolter Jonathan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-13 | Sofinnova Venture Partners X, L.P. | 10% Owner | — | D | Series C Preferred Stock | 2,187,504 | 0.00 | — | 0 | — | ↗ |
| 2021-05-13 | SEIDENBERG BETH C | Director | — | D | Stock Option (right to buy) | 69,043 | 2.90 | 200.0K | 0 | — | ↗ |
| 2021-05-13 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 9,925 | 11.00 | 109.2K | 9,925 | — | ↗ |
| 2021-05-13 | Longitude Capital Partners IV, LLC | 10% Owner | — | I | Series C Preferred Stock | 2,187,504 | 0.00 | — | 0 | — | ↗ |
| 2021-05-13 | Lin Celia | Officer | — | D | Stock Options (right to buy) | 230,821 | 3.94 | 909.3K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
71.71M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Marshall Fordyce, M.D. President and Chief Executive Officer | 660.0K | — | 2.36M | 3.42M | 554.4K | — | 6.99M | 82.62% | ↗ |
| 2 | 2025 | David Johnson Chief Operating Officer | 510.0K | — | 784.9K | 1.14M | 285.6K | 3.0K | 2.72M | 70.65% | ↗ |
| 3 | 2025 | Robert Brenner, M.D. Chief Medical Officer | 509.0K | — | 784.9K | 1.14M | 285.0K | 3.0K | 2.72M | 70.70% | ↗ |
| 4 | 2025 | Sean Grant Chief Financial Officer | 507.0K | — | 784.9K | 1.14M | 283.9K | 3.0K | 2.72M | 70.78% | ↗ |
| 5 | 2025 | William Turner Chief Regulatory Officer | 473.0K | — | 656.6K | 951.8K | 264.9K | — | 2.35M | 68.55% | ↗ |
| 6 | 2024 | Jason Carter Chief Legal Officer | 58.8K | 21.7K | 2.37M | 3.19M | — | — | 5.65M | 98.58% | ↗ |
| 7 | 2024 | Marshall Fordyce, M.D. President and Chief Executive Officer | 616.3K | — | 1.32M | 3.30M | 409.2K | — | 5.65M | 81.84% | ↗ |
| 8 | 2024 | Robert Brenner, M.D. Chief Medical Officer | 476.6K | 120.0K | — | 3.63M | 229.1K | 3.0K | 4.46M | 81.40% | ↗ |
| 9 | 2024 | Sean Grant Chief Financial Officer | 476.1K | — | 441.0K | 1.10M | 229.6K | — | 2.25M | 68.59% | ↗ |
| 10 | 2023 | Marshall Fordyce, M.D. President and Chief Executive Officer | 585.6K | 32.5K | — | 2.52M | 292.1K | — | 3.43M | 73.46% | ↗ |
| 11 | 2023 | Sean Grant Chief Financial Officer | 455.0K | — | — | 1.12M | 184.0K | — | 1.76M | 63.67% | ↗ |
| 12 | 2023 | Celia Lin, M.D. Former Chief Medical Officer | 457.8K | — | — | 559.9K | — | 3.0K | 1.02M | 54.86% | ↗ |
| 13 | 2022 | Marshall Fordyce, M.D. President and Chief Executive Officer | 551.3K | — | 813.8K | 2.46M | 277.6K | — | 4.11M | 79.82% | ↗ |
| 14 | 2022 | Sean Grant Chief Financial Officer | 417.5K | — | 627.8K | 1.26M | 168.0K | 3.0K | 2.48M | 76.22% | ↗ |
| 15 | 2022 | Celia Lin, M.D. Former Chief Medical Officer | 440.5K | — | 232.5K | 733.1K | 176.8K | 3.0K | 1.59M | 60.89% | ↗ |
| 16 | 2022 | Celia Lin, M.D. Chief Medical Officer | 440.5K | — | 232.5K | 733.1K | 176.8K | — | 1.58M | 61.00% | ↗ |
| 17 | 2021 | Sean Grant Chief Financial Officer | 189.5K | 60.0K | — | 1.77M | 67.9K | — | 2.08M | 84.76% | ↗ |
| 18 | 2021 | Marshall Fordyce, M.D. President and Chief Executive Officer | 479.1K | — | — | 770.3K | 236.3K | — | 1.49M | 51.85% | ↗ |
| 19 | 2021 | Celia Lin, M.D. Chief Medical Officer | 361.2K | 150.0K | — | 797.8K | 134.6K | — | 1.44M | 55.26% | ↗ |
| 20 | 2020 | Marshall Fordyce, M.D. President and Chief Executive Officer | 360.0K | — | 316.3K | 2.44M | 108.0K | — | 3.23M | 85.49% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marshall Fordyce | Founder, President, Chief Executive Officer & Director | 1M | — |
| David L. Johnson | Chief Opearating Officer | 798.6K | male |
| Robert Brenner | Chief Medical Officer | 797.0K | — |
| Sean Grant | Chief Financial Officer | 793.9K | male |
| William D. Turner | Chief Regulatory Officer | 737.9K | male |
| Allen Ebens | Executive Vice President of Research | 397.0K | — |
| Gary Barrera | Senior Vice President of Regulatory Affairs & Quality Assurance | — | male |
| Jane Wright-Mitchell | Chief Legal Officer & Secretary | — | — |
| Jim Harrington | SVP of Intellectual Property | — | male |
| Joseph R. Young | Senior Vice President of Finance & Chief Accounting Officer | — | male |
| Julie Person | Chief People Officer | — | female |
| Lijie Zhong | Senior Vice President of Biometrics | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VERA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
